Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NSCLC × rezivertinib × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Carboplatin 6 osimertinib 5 Pemetrexed 4 Drug Therapy 4 tislelizumab 3 anlotinib 3 aflutinib 3 Radiotherapy 3 toripalimab 2 pembrolizumab 2 apatinib 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Radiosurgery 2 Paclitaxel 2 HM781-36B 2 Cisplatin 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 trilaciclib 1 surufatinib 1 sintilimab 1 rezivertinib 1 lenvatinib 1 icotinib 1 envafolimab 1 dacomitinib 1 cemiplimab 1 camrelizumab 1 brigatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03812809 2022-05-19

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

Beta Pharma, Inc.

Phase 2 Completed

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡